For jak1 failure search incyte in news on google. The point is part of azn strategy on solid tumours has unravelled. So they have a gap to fill. Our tyk2 compound is different but similar family.
My link on chk1 failure with azn is different. It shows it is an important target for azn. But their compound had too serious side effects.
This is my point. Its not first to market but best in class. Second mover advantage. If our delays getting here are tweaking molecules to minimise side effects. And we are right. And we are partnered with the experts. We are billionaires
The amounts azn et al have spent on research and trials. The data they have to compare our compounds against ( you can buy our chk1 and tyk2 compounds on the web to test ).
Existing relationship with cruk gives azn merk and overlapping interests in chk1 aurora+flt3.
If we dont get the side effects we are billionaires. There will be a fundraising at some point. But that may not be a share issue but a strategic investment by a big pharma (which would double sp at a stroke )
Sentinel oncology is a wldcard. I suspect they are involved somehow ( more targeted delivey, Linked with cruk and azn , cambridge based) but that is pure speculation by me.
Side effects in p1 key. And does big pharma want to invest in some way prior to p1 results as a hedge. Informed gambling
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.